0Y5F.LSE Endo International PLC
- Market cap
- USD 9.90M
- P/E
- -
- P/B
- -
- ROE
- -
- Dividend yield
- -
- Fundamental score
- -
Ratios use the latest price and the fiscal year ending Dec 2023.
Is 0Y5F.LSE undervalued?
Graham numberThe Graham number of Endo International PLC cannot be estimated reliably (it needs positive earnings and book value).
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
Endo International PLC fundamental analysis
No fundamental analysis for Endo International PLC yet.
Endo International PLC stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About Endo International PLC
Endo International plc, a specialty pharmaceutical company, manufactures and sells generic and branded pharmaceuticals in the United States and internationally. It operates in four segments: Branded Pharmaceuticals, Sterile Injectables, Generic Pharmaceuticals, and International Pharmaceuticals. The company offers branded pharmaceuticals, including XIAFLEX to treat adult patients with Dupuytren's contracture and Peyronie's disease; SUPPRELIN LA to treat central precocious pu…
Full company profileEndo International PLC financial statements
Endo International PLC annual financial statements
| Item | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|---|---|---|---|---|
| Income Statement | ||||||||||
| Revenue | 2.38B | 3.27B | 4.01B | 3.47B | 2.95B | 2.91B | 2.90B | 2.99B | 2.32B | 2.01B |
| Gross Profit | 1.21B | 1.48B | 1.55B | 1.24B | 1.32B | 1.35B | 1.46B | 1.77B | 1.29B | 1.07B |
| Operating Income | 534M | 678M | 599M | 453M | 484M | 582M | 603M | 762M | 383M | 386M |
| EBITDA | 795M | 1.30B | 1.57B | 1.31B | 1.17B | 827M | 1.03B | 473M | -2.15B | -2.08B |
| Net Income | 58.5M | -300M | -3.22B | -1.23B | -962M | -423M | 184M | -613M | -2.92B | -2.45B |
| EPS | 0.37 | -1.52 | -14 | -5.52 | -4.29 | -1.87 | 0.79 | -2.63 | -12 | -10 |
| Balance Sheet | ||||||||||
| Total Assets | 10.8B | 19.4B | 14.3B | 11.6B | 10.1B | 9.39B | 9.26B | 8.77B | 5.76B | 5.14B |
| Total Liabilities | 8.42B | 13.4B | 11.6B | 11.2B | 10.6B | 10.3B | 9.91B | 10.0B | 9.92B | 11.7B |
| Shareholders' Equity | 2.37B | 5.97B | 2.70B | 485M | -498M | -867M | -648M | -1.24B | -4.16B | -6.60B |
| Cash & Short-term Investments | 407M | 272M | 517M | 987M | 1.15B | 1.70B | 1.39B | 1.63B | 1.16B | 946M |
| Total Debt | - | - | 8.14B | 8.24B | 8.22B | 8.49B | 8.40B | 8.32B | 7.42M | 6.47M |
| Cash Flow | ||||||||||
| Operating Cash Flow | 338M | 119M | 528M | 554M | 267M | 98.1M | 397M | 411M | 269M | 435M |
| Capital Expenditure | 80.4M | 81.8M | 139M | 126M | 86.9M | 67.7M | 74.9M | 84.8M | 103M | 94.3M |
| Free Cash Flow | 257M | 36.7M | 389M | 428M | 180M | 30.4M | 323M | 326M | 166M | 341M |
| Ratios | ||||||||||
| ROE | 2.5% | -5.0% | -119.3% | -254.2% | - | - | - | - | - | - |
| ROA | 0.5% | -1.6% | -22.6% | -10.6% | -9.5% | -4.5% | 2.0% | -7.0% | -50.8% | -47.7% |
| Net Profit Margin | 2.5% | -9.2% | -80.4% | -35.5% | -32.6% | -14.5% | 6.3% | -20.5% | -126.1% | -121.8% |
| Debt to Equity | - | - | 3.01x | 17.00x | - | - | - | - | - | - |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Total Debt
- Short and long-term borrowings.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
- Debt to Equity
- Total debt divided by shareholders' equity.
Endo International PLC dividends
- Dividend yield
- -
- Forward dividend
- -
- Payout ratio
- -
- Ex-dividend date
- -
| Fiscal year | Dividends paid | Per share | Payout ratio |
|---|---|---|---|
| 2023 | - | - | - |
| 2022 | - | - | - |
| 2021 | USD 14.8M | 0.06 | - |
| 2020 | - | - | - |
| 2019 | USD 10.2M | 0.04 | - |
| 2018 | - | - | - |
| 2017 | - | - | - |
| 2016 | - | - | - |
| 2015 | - | - | - |
| 2014 | - | - | - |
From the cash flow statement: dividends paid in the fiscal year, divided by that year's shares outstanding. Payout ratio = dividends paid / net income.
Who owns Endo International PLC
- Insiders 0.65%
- Institutions 0.21%
- Public & others 99.14%
- Shares outstanding 224M
- Free float 234M
Endo International PLC company profile
- Company name
- Endo International PLC
- Ticker
- 0Y5F.LSE
- Exchange
- London Exchange
- Sector
- -
- Industry
- Oil, Gas & Consumable Fuels
- Employees
- 2,931
- Fiscal year end
- December
- Address
- Minerva House, Dublin, Ireland, 4
- Phone
- 353 1 268 2000
- Website
- endo.com
About Endo International PLC
Endo International plc, a specialty pharmaceutical company, manufactures and sells generic and branded pharmaceuticals in the United States and internationally. It operates in four segments: Branded Pharmaceuticals, Sterile Injectables, Generic Pharmaceuticals, and International Pharmaceuticals. The company offers branded pharmaceuticals, including XIAFLEX to treat adult patients with Dupuytren's contracture and Peyronie's disease; SUPPRELIN LA to treat central precocious puberty in children; AVEED to treat hypogonadism; NASCOBAL nasal spray to treat vitamin B12 deficiency; QWO, an injectable treatment for moderate to severe cellulite in the buttocks of adult women; PERCOCET for pain management; TESTOPEL, an implantable pellet indicated for TRT in conditions associated with a deficiency or absence of endogenous testosterone; and EDEX to treat erectile dysfunction, as well as opioid products to treat pain associated with post-herpetic neuralgia. It also provides ADRENALIN, a non-selective adrenergic agonist to treat anaphylaxis; VASOSTRICT, a vasopressin IV solution; and APLISOL, which is a sterile aqueous solution, as well as generic sterile injectable products. In addition, the company offers solid oral extended-release, solid oral immediate-release, liquids, semi-solids, patches, powders, ophthalmic products, and sprays. Further, it provides specialty pharmaceutical products and over-the-counter products. The company sells its products to specialty physicians, wholesale distributors, retailers, clinics, government agencies, doctors, retail and specialty pharmacies, and specialty distributors. Endo International plc was founded in 1920 and is headquartered in Dublin, Ireland. On August 16, 2022, Endo International plc, along with its affiliates, filed a voluntary petition for reorganization under Chapter 11 in the U.S. Bankruptcy Court for the Southern District of New York.
Endo International PLC management
10- Mr. Blaise A. ColemanPresident, CEO & Director · born 1974
- Mr. Matthew Joseph MalettaExecutive VP, Chief Legal Officer & Company Secretary · born 1972
- Dr. James Patrick Tursi M.D.Executive Vice President of Global Research & Development · born 1965
- Mr. Mark T. BradleyExecutive VP & CFO · born 1969
- Frank B. RacitiVP, Controller & Chief Accounting Officer
- Ms. Cheryl StouchSenior VP of Information Technology & Chief Information Officer
- Ms. Laure E. ParkSenior Vice President of Investor Relations & Corporate Affairs
- Ms. Susan WilliamsonSenior VP & Chief Compliance Officer
- Ms. Tracy BassoChief Human Resources Officer
- Mr. Patrick A. BarryExecutive VP & President of Global Commercial Operations · born 1968